These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 17317831

  • 1. Phase I/II study of bortezomib plus docetaxel in patients with advanced androgen-independent prostate cancer.
    Dreicer R, Petrylak D, Agus D, Webb I, Roth B.
    Clin Cancer Res; 2007 Feb 15; 13(4):1208-15. PubMed ID: 17317831
    [Abstract] [Full Text] [Related]

  • 2. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN, Daliani DD, Nix D, Yang H, Madden T, Wang X, Pien CS, Millikan RE, Tu SM, Pagliaro L, Kim J, Adams J, Elliott P, Esseltine D, Petrusich A, Dieringer P, Perez C, Logothetis CJ.
    J Clin Oncol; 2004 Jun 01; 22(11):2108-21. PubMed ID: 15169797
    [Abstract] [Full Text] [Related]

  • 3. Weekly docetaxel and bortezomib as first-line treatment for patients with hormone-refractory prostate cancer: a Minnie Pearl Cancer Research Network phase II trial.
    Hainsworth JD, Meluch AA, Spigel DR, Barton J, Simons L, Meng C, Gould B, Greco FA.
    Clin Genitourin Cancer; 2007 Mar 01; 5(4):278-83. PubMed ID: 17553208
    [Abstract] [Full Text] [Related]

  • 4. Phase I trial of bortezomib in combination with docetaxel in patients with advanced solid tumors.
    Messersmith WA, Baker SD, Lassiter L, Sullivan RA, Dinh K, Almuete VI, Wright JJ, Donehower RC, Carducci MA, Armstrong DK.
    Clin Cancer Res; 2006 Feb 15; 12(4):1270-5. PubMed ID: 16489083
    [Abstract] [Full Text] [Related]

  • 5. Phase I study of sorafenib in combination with docetaxel and prednisone in chemo-naïve patients with metastatic castration-resistant prostate cancer.
    Mardjuadi F, Medioni J, Kerger J, D'Hondt L, Canon JL, Duck L, Musuamba F, Oudard S, Clausse M, Moxhon A, Machiels JP.
    Cancer Chemother Pharmacol; 2012 Aug 15; 70(2):293-303. PubMed ID: 22752248
    [Abstract] [Full Text] [Related]

  • 6. A phase I study of paclitaxel/doxorubicin/ thalidomide in patients with androgen- independent prostate cancer.
    Amato RJ, Sarao H.
    Clin Genitourin Cancer; 2006 Mar 15; 4(4):281-6. PubMed ID: 16729912
    [Abstract] [Full Text] [Related]

  • 7. Diethylstilbestrol and docetaxel: a Phase II study of tubulin active agents in patients with metastatic, androgen-independent prostate cancer.
    Montgomery RB, Nelson PS, Lin D, Ryan CW, Garzotto M, Beer TM.
    Cancer; 2007 Sep 01; 110(5):996-1002. PubMed ID: 17639587
    [Abstract] [Full Text] [Related]

  • 8. Docetaxel plus prednisone versus mitoxantrone plus prednisone for metastatic hormone-refractory prostate cancer in Chinese patients: experience of a single center.
    Zhang HL, Ye DW, Yao XD, Dai B, Zhang SL, Shen YJ, Zhu Y, Zhang W.
    Urol Int; 2007 Sep 01; 79(4):307-11. PubMed ID: 18025847
    [Abstract] [Full Text] [Related]

  • 9. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators.
    Beer TM, Ryan CW, Venner PM, Petrylak DP, Chatta GS, Ruether JD, Redfern CH, Fehrenbacher L, Saleh MN, Waterhouse DM, Carducci MA, Vicario D, Dreicer R, Higano CS, Ahmann FR, Chi KN, Henner WD, Arroyo A, Clow FW, ASCENT Investigators.
    J Clin Oncol; 2007 Feb 20; 25(6):669-74. PubMed ID: 17308271
    [Abstract] [Full Text] [Related]

  • 10. High dose pulse calcitriol, docetaxel and estramustine for androgen independent prostate cancer: a phase I/II study.
    Tiffany NM, Ryan CW, Garzotto M, Wersinger EM, Beer TM.
    J Urol; 2005 Sep 20; 174(3):888-92. PubMed ID: 16093981
    [Abstract] [Full Text] [Related]

  • 11. Docetaxel, estramustine and prednisone for hormone-refractory prostate cancer: a single-center experience.
    Boehmer A, Anastasiadis AG, Feyerabend S, Nagele U, Kuczyk M, Schilling D, Corvin S, Merseburger AS, Stenzl A.
    Anticancer Res; 2005 Sep 20; 25(6C):4481-6. PubMed ID: 16334130
    [Abstract] [Full Text] [Related]

  • 12. Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer.
    Oudard S, Banu E, Beuzeboc P, Voog E, Dourthe LM, Hardy-Bessard AC, Linassier C, Scotté F, Banu A, Coscas Y, Guinet F, Poupon MF, Andrieu JM.
    J Clin Oncol; 2005 May 20; 23(15):3343-51. PubMed ID: 15738542
    [Abstract] [Full Text] [Related]

  • 13. Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial.
    Lara PN, Koczywas M, Quinn DI, Lenz HJ, Davies AM, Lau DH, Gumerlock PH, Longmate J, Doroshow JH, Schenkein D, Kashala O, Gandara DR.
    J Thorac Oncol; 2006 Feb 20; 1(2):126-34. PubMed ID: 17409841
    [Abstract] [Full Text] [Related]

  • 14. Platelet-derived growth factor receptor inhibitor imatinib mesylate and docetaxel: a modular phase I trial in androgen-independent prostate cancer.
    Mathew P, Thall PF, Jones D, Perez C, Bucana C, Troncoso P, Kim SJ, Fidler IJ, Logothetis C.
    J Clin Oncol; 2004 Aug 15; 22(16):3323-9. PubMed ID: 15310776
    [Abstract] [Full Text] [Related]

  • 15. Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
    Ferrero JM, Chamorey E, Oudard S, Dides S, Lesbats G, Cavaglione G, Nouyrigat P, Foa C, Kaphan R.
    Cancer; 2006 Aug 15; 107(4):738-45. PubMed ID: 16826591
    [Abstract] [Full Text] [Related]

  • 16. Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer.
    Fanucchi MP, Fossella FV, Belt R, Natale R, Fidias P, Carbone DP, Govindan R, Raez LE, Robert F, Ribeiro M, Akerley W, Kelly K, Limentani SA, Crawford J, Reimers HJ, Axelrod R, Kashala O, Sheng S, Schiller JH.
    J Clin Oncol; 2006 Nov 01; 24(31):5025-33. PubMed ID: 17075122
    [Abstract] [Full Text] [Related]

  • 17. A phase II trial of bortezomib and prednisone for castration resistant metastatic prostate cancer.
    Morris MJ, Kelly WK, Slovin S, Ryan C, Eicher C, Heller G, Scher HI.
    J Urol; 2007 Dec 01; 178(6):2378-83; discussion 2383-4. PubMed ID: 17936848
    [Abstract] [Full Text] [Related]

  • 18. Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors.
    Cohen SJ, Engstrom PF, Lewis NL, Langer CJ, McLaughlin S, Beard M, Weiner LM, Meropol NJ.
    Am J Clin Oncol; 2008 Feb 01; 31(1):1-5. PubMed ID: 18376220
    [Abstract] [Full Text] [Related]

  • 19. Weekly docetaxel as second line treatment after mitozantrone for androgen-independent prostate cancer.
    Joshua AM, Nordman I, Venkataswaran R, Clarke S, Stockler MR, Boyer MJ.
    Intern Med J; 2005 Aug 01; 35(8):468-72. PubMed ID: 16176469
    [Abstract] [Full Text] [Related]

  • 20. Effect of docetaxel in patients with hormone-dependent prostate-specific antigen progression after local therapy for prostate cancer.
    Goodin S, Medina P, Capanna T, Shih WJ, Abraham S, Winnie J, Doyle-Lindrud S, Todd M, DiPaola RS.
    J Clin Oncol; 2005 May 20; 23(15):3352-7. PubMed ID: 15738531
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.